| Literature DB >> 26022168 |
Guy Helman1, Keith Van Haren2, Maria L Escolar3, Adeline Vanderver4.
Abstract
The leukodystrophies are a heterogeneous group of inherited disorders with broad clinical manifestations and variable pathologic mechanisms. Improved diagnostic methods have allowed identification of the underlying cause of these diseases, facilitating identification of their pathologic mechanisms. Clinicians are now able to prioritize treatment strategies and advance research in therapies for specific disorders. Although only a few of these disorders have well-established treatments or therapies, a number are on the verge of clinical trials. As investigators are able to shift care from symptomatic management of disorders to targeted therapeutics, the unmet therapeutic needs could be reduced for these patients.Entities:
Keywords: Disease modifying; Gene therapy; Genomics; Leukodystrophy; Stem cell; Symptomatic; Therapy
Mesh:
Year: 2015 PMID: 26022168 PMCID: PMC5712822 DOI: 10.1016/j.pcl.2015.03.006
Source DB: PubMed Journal: Pediatr Clin North Am ISSN: 0031-3955 Impact factor: 3.278